Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: An Analysis of the DARE-19 Randomized Controlled Trial.
Clinical journal of the American Society of Nephrology : CJASN（2022）
摘要
The effects of dapagliflozin on primary and secondary outcomes in hospitalized participants with COVID-19 were consistent in those with eGFR below/above 60 ml/min per 1.73 m. Dapagliflozin was well tolerated and did not increase the risk of AKI in participants with eGFR below or above 60 ml/min per 1.73 m.
更多查看译文
关键词
COVID-19,acute kidney injury,cardiovascular disease,chronic kidney disease,diabetes,heart failure,hospitalization,mortality risk,outcomes,randomized controlled trials
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要